BFC Planning’s Viridian Therapeutics VRDN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$597 Hold
29
– – ﹤0.01% 3265
2026
Q2
$533 Hold
29
– – ﹤0.01% 3245
2026
Q1
$567 Buy
+29
New +$861 ﹤0.01% 2841

Other funds holding VRDN

BFC Planning's VRDN Position: Q3 2026 in Review

BFC Planning held its Viridian Therapeutics (VRDN) position steady in Q3 2026 at 29 shares worth $597. The position accounts for ﹤0.01% of the portfolio, ranked #3265.

BFC Planning first reported a position in VRDN in Q1 2026 and has held it in 3 quarters since. 154 funds tracked by Wall St. Rank hold VRDN as of Q3 2026.

  • BFC Planning held 29 shares of Viridian Therapeutics worth $597 as of Q3 2026.
  • BFC Planning left its Viridian Therapeutics share count unchanged in Q3 2026.
  • Viridian Therapeutics made up ﹤0.01% of BFC Planning's portfolio in Q3 2026, its #3265 holding.
  • BFC Planning first reported a position in Viridian Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • 154 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2026.

Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.